Drug Profile
Research programme: antifungals - Basilea
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Basilea Pharmaceutica
- Class
- Mechanism of Action Cell wall inhibitors; DNA synthesis inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in Switzerland
- 16 Mar 2009 Preclinical development is ongoing in Switzerland
- 12 Feb 2007 Preclinical development is ongoing